project id: TCGA-PRAD; case submitter id: TCGA-ZG-A9N3; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.83; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.89; rna integrity number: 7.1; age at index: 73; days to birth: -26902; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1940; age at diagnosis: 26902; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N1; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 349.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 69; initial weight: 210.0; sample id: 473e6120-b20d-4358-acb0-c65a35e20d6a; sample submitter id: TCGA-ZG-A9N3-01A; portion id: df443e24-0a19-4685-b38c-a296d5aebde6; portion submitter id: TCGA-ZG-A9N3-01A-11; slide id: e24427fe-d909-4e15-a4b6-9121477ba5e0; slide submitter id: TCGA-ZG-A9N3-01A-01-TSA; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 1.0; percent necrosis: 1.0; percent neutrophil infiltration: 1.0; percent normal cells: 0.0; percent stromal cells: 19.0; percent tumor cells: 80.0; percent tumor nuclei: 80.0; section location: TOP;